Why Cannabis Operators Are Quietly Buying Back Stock
By Sheeba M. | April 27, 2026 Why Cannabis Operators Are Quietly Buying Back Stock TL;DR: With cannabis stocks trading at historically depressed valuations, MSOs are authorizing buybacks not out of confidence—but because diluted share counts are crushing EPS growth. It’s financial engineering at its finest. Quietly, without fanfare, cannabis operators are putting money back […]
GLP-1 Diet Drugs Are Killing Cannabis Sales (Here’s Why)
By Sheeba M. | April 25, 2026 “GLP-1 Weight Loss Boom Quietly Reshaping the $40B Cannabis Market” TL;DR Dispensaries are adjusting product offerings as GLP-1 weight-loss drugs (Ozempic, Wegovy) reshape consumer behavior. Users report diminished cannabis cravings while on these therapies. With FDA approval of higher-dose Wegovy in March 2026, the trend is accelerating—and MSOs […]
Cannabis M&A Isn’t Dead—It’s Just Invisible Now
By Sheeba M. | April 25, 2026 “Why Cannabis M&A in 2026 Will Look Nothing Like Past Deals” TL;DR April 2026 saw 11 cannabis transactions, but none followed the “transformative consolidation” playbook. Instead: distressed exits, private deals, and state-level tuck-ins. Public MSOs remain constrained by low valuations and refinancing needs. The M&A wave investors predicted […]